ABSTRACT
The seminal description of the cellular restriction factor APOBEC3G and its antagonism by HIV-1 Vif has underpinned two decades of research on the host-virus interaction. We recently reported that HIV-1 Vif is also able to degrade the PPP2R5 family of regulatory subunits of key cellular phosphatase PP2A (PPP2R5A-E; Greenwood et al., 2016; Naamati et al., 2019). We now identify amino acid polymorphisms at positions 31 and 128 of HIV-1 Vif which selectively regulate the degradation of PPP2R5 family proteins. These residues covary across HIV-1 viruses in vivo, favouring depletion of PPP2R5A-E. Through analysis of point mutants and naturally occurring Vif variants, we further show that degradation of PPP2R5 family subunits is both necessary and sufficient for Vif-dependent G2/M cell cycle arrest. Antagonism of PP2A by HIV-1 Vif is therefore independent of APOBEC3 family proteins, and regulates cell cycle progression in HIV-infected cells.
Subject(s)
Cell Cycle Checkpoints , HIV-1/genetics , Protein Phosphatase 2/metabolism , vif Gene Products, Human Immunodeficiency Virus/physiology , APOBEC Deaminases/metabolism , Flow Cytometry , HIV-1/physiology , Host Microbial Interactions , Humans , Point Mutation/genetics , vif Gene Products, Human Immunodeficiency Virus/geneticsABSTRACT
The virion infectivity factor (Vif) open reading frame is conserved among most lentiviruses. Vif molecules contribute to viral replication by inactivating host antiviral factors, the APOBEC3 cytidine deaminases. However, various species of lentiviral Vif proteins have evolved different strategies for overcoming host APOBEC3. Whether different species of lentiviral Vif proteins still preserve certain common features has not been reported. Here, we show for the first time that diverse lentiviral Vif molecules maintain the ability to interact with the human immunodeficiency virus type 1 (HIV-1) Gag precursor (Pr55Gag) polyprotein. Surprisingly, bovine immunodeficiency virus (BIV) Vif, but not HIV-1 Vif, interfered with HIV-1 production and viral infectivity even in the absence of APOBEC3. Further analysis revealed that BIV Vif demonstrated an enhanced interaction with Pr55Gag compared to that of HIV-1 Vif, and BIV Vif defective for the Pr55Gag interaction lost its ability to inhibit HIV-1. The C-terminal region of capsid (CA) and the p2 region of Pr55Gag, which are important for virus assembly and maturation, were involved in the interaction. Transduction of CD4+ T cells with BIV Vif blocked HIV-1 replication. Thus, the conserved Vif-Pr55Gag interaction provides a potential target for the future development of antiviral strategies.IMPORTANCE The conserved Vif accessory proteins of primate lentiviruses HIV-1, simian immunodeficiency virus (SIV), and BIV all form ubiquitin ligase complexes to target host antiviral APOBEC3 proteins for degradation, with different cellular requirements and using different molecular mechanisms. Here, we demonstrate that BIV Vif can interfere with HIV-1 Gag maturation and suppress HIV-1 replication through interaction with the precursor of the Gag (Pr55Gag) of HIV-1 in virus-producing cells. Moreover, the HIV-1 and SIV Vif proteins are conserved in terms of their interactions with HIV-1 Pr55Gag although HIV-1 Vif proteins bind Pr55Gag less efficiently than those of BIV Vif. Our research not only sheds new light on this feature of these conserved lentiviral Vif proteins but also provides a formerly unrecognized target for the development of antiviral strategies. Since increasing the Vif-Pr55Gag interaction could potentially suppress virus proliferation, this approach could offer a new strategy for the development of HIV inhibitors.
Subject(s)
HIV-1/physiology , Immunodeficiency Virus, Bovine/physiology , Virus Replication , vif Gene Products, Human Immunodeficiency Virus/physiology , Amino Acid Sequence , Conserved Sequence , HEK293 Cells , Humans , Models, Molecular , Protein Interaction Domains and Motifs , Protein Processing, Post-Translational , Species Specificity , gag Gene Products, Human Immunodeficiency VirusABSTRACT
UNLABELLED: HIV-1 is characterized by high genetic heterogeneity which is a challenge for developing therapeutics. Therefore, it is necessary to understand the extent of genetic variations that HIV is undergoing in North India. The objective of this study was to determine the role of genetic and functional role of Vif on APOBEC3G degradation. Vif is an accessory protein involved in counteracting APOBEC3/F proteins. Genetic analysis of Vif variants revealed that Vif C variants were closely related to South African Vif C whereas Vif B variants and Vif B/C showed distinct geographic locations. This is the first report to show the emergence of Vif B/C in our population. The functional domains, motifs and phosphorylation sites were well conserved. Vif C variants differed in APOBEC3G degradation from Vif B variants. Vif B/C revealed similar levels of APOBEC3G degradation to Vif C confirming the presence of genetic determinants in C-terminal region. High genetic diversity was observed in Vif variants which may cause the emergence of more complex and divergent strains. These results reveal the genetic determinants of Vif in mediating APOBEC3G degradation and highlight the genetic information for the development of anti-viral drugs against HIV. IMPORTANCE: Vif is an accessory HIV-1 protein which plays significant role in the degradation of human DNA-editing factor APOBEC3G, thereby impeding the antiretroviral activity of APOBEC3G. It is known that certain natural polymorphisms in Vif could degrade APOBEC3G relatively higher rate, suggesting its role in HIV-1 pathogenesis. This is the first report from North India showcasing genetic variations and novel polymorphisms in Vif gene. Subtype C is prevalent in India, but for the first time we observed putative B/C recombinants with a little high ability to degrade APOBEC3G indicating adaptation and evolving nature of virus in our population. Indian Vif C variants were able to degrade APOBEC3G well in comparison to Vif B variants. These genetic changes were most likely selected during adaptation of HIV to our population. These results elucidate that the genetic determinants of Vif and highlights the potential targets for therapeutics.
Subject(s)
Cytidine Deaminase/metabolism , Recombination, Genetic , vif Gene Products, Human Immunodeficiency Virus/physiology , APOBEC-3G Deaminase , Amino Acid Sequence , HIV-1/genetics , Humans , India , Molecular Sequence Data , Phylogeny , Proteolysis , Sequence Homology, Amino Acid , vif Gene Products, Human Immunodeficiency Virus/chemistry , vif Gene Products, Human Immunodeficiency Virus/geneticsABSTRACT
Pathogens such as HIV-1, with their minimalist genomes, must navigate cellular networks and rely on hijacking and manipulating the host machinery for successful replication. Limited overlap of host factors identified as vital for pathogen replication may be explained by considering that pathogens target, rather than specific cellular factors, crucial cellular pathways by targeting different, functionally equivalent, protein-protein interactions within that pathway. The ability to utilize alternative routes through cellular pathways may be essential for pathogen survival when restricted and provide flexibility depending on the viral replication stage and the environment in the infected host. In this minireview, we evaluate evidence supporting this notion, discuss specific HIV-1 examples, and consider the molecular mechanisms which allow pathogens to flexibly exploit different routes.
Subject(s)
HIV Infections/virology , HIV-1/pathogenicity , Active Transport, Cell Nucleus , Animals , Cytidine Deaminase/physiology , HIV-1/genetics , HIV-1/physiology , Host-Pathogen Interactions , Humans , Lentivirus/pathogenicity , Lentivirus/physiology , Lentivirus Infections/virology , Models, Biological , Virus Integration , Virus Replication , vif Gene Products, Human Immunodeficiency Virus/physiologyABSTRACT
The HIV-1 accessory protein Vif hijacks a cellular Cullin-RING ubiquitin ligase, CRL5, to promote degradation of the APOBEC3 (A3) family of restriction factors. Recently, the cellular transcription cofactor CBFß was shown to form a complex with CRL5-Vif and to be essential for A3 degradation and viral infectivity. We now demonstrate that CBFß is required for assembling a well-ordered CRL5-Vif complex by inhibiting Vif oligomerization and by activating CRL5-Vif via direct interaction. The CRL5-Vif-CBFß holoenzyme forms a well-defined heterohexamer, indicating that Vif simultaneously hijacks CRL5 and CBFß. Heterodimers of CBFß and RUNX transcription factors contribute toward the regulation of genes, including those with immune system functions. We show that binding of Vif to CBFß is mutually exclusive with RUNX heterodimerization and impacts the expression of genes whose regulatory domains are associated with RUNX1. Our results provide a mechanism by which a pathogen with limited coding capacity uses one factor to hijack multiple host pathways.
Subject(s)
CCAAT-Binding Factor/metabolism , Core Binding Factor Alpha 2 Subunit/metabolism , Cytosine Deaminase/metabolism , Gene Expression Regulation , vif Gene Products, Human Immunodeficiency Virus/metabolism , APOBEC Deaminases , Amino Acid Sequence , Base Sequence , CCAAT-Binding Factor/chemistry , CCAAT-Binding Factor/physiology , Consensus Sequence , Core Binding Factor Alpha 2 Subunit/chemistry , Core Binding Factor Alpha 2 Subunit/physiology , Cytidine Deaminase , Cytosine Deaminase/chemistry , Cytosine Deaminase/physiology , Gene Expression , Genes, Reporter , HEK293 Cells , HIV-1/physiology , Host-Pathogen Interactions , Humans , Hydrophobic and Hydrophilic Interactions , Models, Molecular , Molecular Sequence Data , Protein Binding , Protein Interaction Domains and Motifs , Protein Multimerization , Protein Processing, Post-Translational , Protein Stability , Protein Structure, Quaternary , T-Lymphocytes/metabolism , T-Lymphocytes/virology , Ubiquitination , vif Gene Products, Human Immunodeficiency Virus/chemistry , vif Gene Products, Human Immunodeficiency Virus/physiologyABSTRACT
The genetic diversity of HIV-1 represents a major challenge in vaccine development. In this study, we establish a rationale for eliminating HIV-1-infected cells by targeting cellular immune responses against stable human endogenous retroviral (HERV) antigens. HERV DNA sequences in the human genome represent the remnants of ancient infectious retroviruses. We show that the infection of CD4+ T cells with HIV-1 resulted in transcription of the HML-2 lineage of HERV type K [HERV-K(HML-2)] and the expression of Gag and Env proteins. HERV-K(HML-2)-specific CD8+ T cells obtained from HIV-1-infected human subjects responded to HIV-1-infected cells in a Vif-dependent manner in vitro. Consistent with the proposed mode of action, a HERV-K(HML-2)-specific CD8+ T cell clone exhibited comprehensive elimination of cells infected with a panel of globally diverse HIV-1, HIV-2, and SIV isolates in vitro. We identified a second T cell response that exhibited cross-reactivity between homologous HIV-1-Pol and HERV-K(HML-2)-Pol determinants, raising the possibility that homology between HIV-1 and HERVs plays a role in shaping, and perhaps enhancing, the T cell response to HIV-1. This justifies the consideration of HERV-K(HML-2)-specific and cross-reactive T cell responses in the natural control of HIV-1 infection and for exploring HERV-K(HML-2)-targeted HIV-1 vaccines and immunotherapeutics.
Subject(s)
CD4-Positive T-Lymphocytes/virology , Endogenous Retroviruses/physiology , HIV-1/physiology , HIV-2/physiology , Immunity, Cellular , Simian Immunodeficiency Virus/physiology , Amino Acid Sequence , Animals , Antigens, Viral/genetics , Antigens, Viral/immunology , Antigens, Viral/metabolism , CD4-Positive T-Lymphocytes/immunology , Cells, Cultured , Endogenous Retroviruses/immunology , Endogenous Retroviruses/metabolism , Gene Expression Regulation, Viral , Gene Products, gag/genetics , Gene Products, gag/immunology , Gene Products, gag/metabolism , HIV Infections/immunology , HIV Infections/virology , HIV-1/immunology , HIV-1/isolation & purification , HIV-2/immunology , HIV-2/isolation & purification , Host-Pathogen Interactions , Humans , Molecular Sequence Data , Simian Immunodeficiency Virus/immunology , Simian Immunodeficiency Virus/isolation & purification , Transcriptional Activation , Viral Envelope Proteins/genetics , Viral Envelope Proteins/immunology , Viral Envelope Proteins/metabolism , Virus Integration , Virus Internalization , vif Gene Products, Human Immunodeficiency Virus/physiologySubject(s)
HIV Infections/immunology , HIV-1/physiology , Immunity, Cellular/genetics , Transcription Factors/physiology , Animals , CCAAT-Binding Factor/genetics , CCAAT-Binding Factor/metabolism , CCAAT-Binding Factor/physiology , HIV Infections/genetics , HIV-1/immunology , Humans , Models, Biological , Proteolysis , Transcription Factors/genetics , Transcription Factors/metabolism , Ubiquitination/genetics , Ubiquitination/physiology , vif Gene Products, Human Immunodeficiency Virus/metabolism , vif Gene Products, Human Immunodeficiency Virus/physiologyABSTRACT
Human cells developed the defense systems against retrovirus infections during the evolutions. These systems include retroviral restrictions by DNA cytidine deaminases of APOBEC3 family (A, B, C, DE, F, G, and H), which are potent factors to block the viral replication by blocking reverse transcription and/or integration and by hypermutating viral cDNA. In case of HIV-1, the viral protein, Vif abrogates the APOBEC3F/G function through specific machinery of ubiquitination and proteasomal degradation. Without Vif, APOBEC3F/G are incorporated into virus particles and block reverse transcription and/or integration in a newly infected cell. Recent advances in our understanding about biochemical and structure-biological characteristics of the enzymes provide new insights to reveal more detailed molecular mechanisms for anti-retroviral activity by APOBEC3 family. Here I briefly review how APOBEC3 proteins block retrovirus replications, focusing on APOBEC3G.
Subject(s)
Anti-Retroviral Agents , Cytosine Deaminase/pharmacology , Cytosine Deaminase/physiology , Retroviridae/genetics , Retroviridae/physiology , Virus Replication/genetics , APOBEC Deaminases , APOBEC-3G Deaminase , Cytidine Deaminase , Cytosine Deaminase/chemistry , DNA, Complementary/genetics , DNA, Viral/genetics , HIV-1 , Humans , Multigene Family , Mutation , Reverse Transcription , Ubiquitination , Virus Integration , vif Gene Products, Human Immunodeficiency Virus/physiologyABSTRACT
The presence of siRNA against adapter-related protein complex 2 alpha 1 subunit (AP2alpha) enhances human immunodeficiency virus type 1 (HIV-1) replication by up-regulating nuclear transport of viral genome. In this report, we examined possible viral factors involved in AP2alpha-mediated regulation of HIV-1 replication, namely, Gag matrix protein (MA), integrase (IN) and Vpr. Replication of mutant viruses lacking the nucleophilic property of one of these viral proteins was significantly enhanced by treating cells with AP2alpha siRNA, indicating that Gag MA, IN or Vpr is not specifically involved in AP2alpha-mediated enhancement of viral replication. In contrast, AP2alpha siRNA showed no effect on the level of gene transduction mediated by HIV-1-derived lentiviral vector (LV). Although virus-like LV particle and parental HIV-1 particle are composed of almost equivalent viral structural proteins, LV particles lack three accessory proteins, Vif, Vpr and Vpu, and a large portion of the HIV-1 genome. Vif, Vpr and Vpu were dispensable for AP2alpha siRNA-mediated enhancement of HIV-1 replication, indicating that a particular part of the HIV-1 genomic fragment deleted in the LV genome might be required for the enhancing effect of AP2alpha siRNA on viral replication. Taken together, these results suggest that an as yet undetermined gene fragment of the HIV-1 genome is involved in AP2alpha-mediated regulation of HIV-1 replication.
Subject(s)
Adaptor Protein Complex 2/physiology , Adaptor Protein Complex alpha Subunits/physiology , Gene Products, gag/physiology , Gene Products, vpr/physiology , HIV-1/physiology , Integrases/physiology , Virus Replication/genetics , Virus Replication/physiology , Adaptor Protein Complex 2/genetics , Adaptor Protein Complex alpha Subunits/genetics , Gene Expression Regulation/genetics , Gene Expression Regulation/physiology , Gene Products, gag/genetics , Gene Products, vpr/genetics , HIV-1/genetics , Human Immunodeficiency Virus Proteins/physiology , Humans , Integrases/genetics , RNA, Small Interfering/genetics , RNA, Small Interfering/physiology , Viral Regulatory and Accessory Proteins/physiology , vif Gene Products, Human Immunodeficiency Virus/physiologyABSTRACT
In this paper, we show how a game theoretic analysis can provide a model to explain the interdependence of host produced APOBEC3G levels and virus encoded Vif levels. We then use the relationship between these two opposing proteins in order to predict the success of two different HIV-1 viral variants, R5 and X4. From our analysis, we show that when APOBEC3G strongly favors mutation from an R5 strain to an X4 strain, it can be optimal for HIV-1 to suppress transmission of the X4 variant, despite the loss of X4 fitness potential. This is particularly true when the X4 strain significantly interferes with the host adaptive immune response, when Vif production is limited, or when host APOBEC3G targets the X4 strain more severely than the R5 strain. Using the proposed game theoretic analysis, we show that transmitting only R5 viruses has two advantages so far as HIV-1 is concerned. First, it allows for an increased R5 viral load due to immune interference caused by the X4 strain, and second, it forces the host to down-regulate APOBEC3G production, which is automatically favorable to the virus. APOBEC3G down-regulation, which is predicted in our model for a wide range of parameter values, may offer an explanation for the observed low level of APOBEC3G transcription and translation in hosts infected with HIV-1.
Subject(s)
HIV-1/genetics , HIV-1/pathogenicity , Receptors, CCR5/physiology , Receptors, CXCR4/physiology , APOBEC-3G Deaminase , Cytidine Deaminase/physiology , Game Theory , Genetic Variation , HIV Infections/immunology , HIV Infections/physiopathology , HIV Infections/virology , HIV-1/immunology , Host-Pathogen Interactions , Humans , Mathematical Concepts , Models, Biological , vif Gene Products, Human Immunodeficiency Virus/genetics , vif Gene Products, Human Immunodeficiency Virus/physiologyABSTRACT
HIV-1 depends on host-cell resources for replication, access to which may be limited to a particular phase of the cell cycle. The HIV-encoded proteins Vpr (viral protein R) and Vif (viral infectivity factor) arrest cells in the G2 phase; however, alteration of other cell-cycle phases has not been reported. We show that Vif drives cells out of G1 and into the S phase. The effect of Vif on the G1- to-S transition is distinct from its effect on G2, because G2 arrest is Cullin5-dependent, whereas the G1- to-S progression is Cullin5-independent. Using mass spectrometry, we identified 2 novel cellular partners of Vif, Brd4 and Cdk9, both of which are known to regulate cell-cycle progression. We confirmed the interaction of Vif and Cdk9 by immunoprecipitation and Western blot, and showed that small interfering RNAs (siRNAs) specific for Cdk9 inhibit the Vif-mediated G1- to-S transition. These data suggest that Vif regulates early cell-cycle progression, with implications for infection and latency.
Subject(s)
Cell Cycle/genetics , Cell Proliferation , vif Gene Products, Human Immunodeficiency Virus/physiology , Cell Cycle/drug effects , Cell Cycle/physiology , Cell Proliferation/drug effects , Cullin Proteins/genetics , Cullin Proteins/metabolism , Cullin Proteins/physiology , Cyclin-Dependent Kinase 9/antagonists & inhibitors , Cyclin-Dependent Kinase 9/genetics , Cyclin-Dependent Kinase 9/metabolism , G1 Phase/drug effects , G1 Phase/genetics , G1 Phase/physiology , Gene Expression Regulation/drug effects , HIV Infections/genetics , HIV Infections/metabolism , HIV Infections/pathology , HIV-1/genetics , HIV-1/physiology , HeLa Cells , Humans , Models, Biological , Mutant Proteins/genetics , Mutant Proteins/metabolism , Protein Binding/drug effects , Protein Binding/physiology , RNA, Small Interfering/pharmacology , S Phase/drug effects , S Phase/genetics , S Phase/physiology , Transfection , Virus Latency/drug effects , Virus Latency/genetics , vif Gene Products, Human Immunodeficiency Virus/genetics , vif Gene Products, Human Immunodeficiency Virus/metabolismABSTRACT
Viruses, including retroviruses like human immunodeficiency virus (HIV) and mouse mammary tumor virus (MMTV), are transmitted from mother to infants through milk. Lymphoid cells and antibodies are thought to provide mammary gland and milk-borne immunity. In contrast, little is known about the role of mammary epithelial cells (MECs). The APOBEC3 family of retroviral restriction factors is highly expressed in macrophages and lymphoid and dendritic cells. We now show that APOBEC3 proteins are also expressed in mouse and human MECs. Lymphoid cell-expressed APOBEC3 restricts in vivo spread of MMTV to lymphoid and mammary tissue. In contrast, mammary gland-expressed APOBEC3 is packaged into MMTV virions and decreases the infectivity of milk-borne viruses. Moreover, APOBEC3G and other APOBEC3 genes are expressed in human mammary cells and have the potential to restrict viruses produced in this cell type. These data point to a role for APOBEC3 proteins in limiting infectivity of milk-transmitted viruses.
Subject(s)
Cytidine Deaminase/physiology , Epithelial Cells/metabolism , Mammary Glands, Animal/metabolism , Mammary Glands, Human/metabolism , Mammary Tumor Virus, Mouse/physiology , Milk/virology , Retroviridae Infections/metabolism , APOBEC Deaminases , Animals , Cells, Cultured , Cytidine Deaminase/biosynthesis , Cytosine Deaminase/biosynthesis , Cytosine Deaminase/physiology , Epithelial Cells/virology , Female , HIV-1/pathogenicity , Humans , Infectious Disease Transmission, Vertical , Lymphocytes/metabolism , Mammary Glands, Animal/virology , Mammary Glands, Human/virology , Mammary Tumor Virus, Mouse/pathogenicity , Mice , Mice, Inbred C57BL , Mice, Knockout , Neoplasms, Experimental/metabolism , Neoplasms, Experimental/virology , Retroviridae Infections/transmission , Retroviridae Infections/virology , Tumor Virus Infections/metabolism , Tumor Virus Infections/transmission , Tumor Virus Infections/virology , Virion/physiology , Virus Assembly , vif Gene Products, Human Immunodeficiency Virus/physiologyABSTRACT
Human immunodeficiency virus type 1 (HIV-1) viral infectivity factor (Vif), one of the accessory proteins, which is a small basic phosphoprotein, is essential for viral replication and pathogenesis. The best well-characterized function of Vif is its ability to neutralize the host cell antiviral factor, apolipoprotein B mRNA editing enzyme catalytic polypeptide like 3G (APOBEC3G), which makes the viral particles more infective. In addition, Vif can regulate the reverse transcription and the advanced stage of replication of the virus particle, as well as induce the termination of cell cycle at G2 stage and so on. The designed drug aimed directly at Vif can efficiently block the maturation and infectivity of HIV-1. In this review, the structure, function and especially the related inhibitors of Vif are reviewed.
Subject(s)
Anti-HIV Agents/pharmacology , Cytidine Deaminase/metabolism , HIV-1/physiology , vif Gene Products, Human Immunodeficiency Virus/antagonists & inhibitors , APOBEC-3G Deaminase , Amino Acid Sequence , Ethylenediamines/pharmacology , Humans , Reverse Transcription , Virus Replication , vif Gene Products, Human Immunodeficiency Virus/genetics , vif Gene Products, Human Immunodeficiency Virus/metabolism , vif Gene Products, Human Immunodeficiency Virus/physiologyABSTRACT
Tandem stop mutations K26X and H27X in human immunodeficiency virus type 1 (HIV-1) vif compromise virus replication in human T-cell lines that stably express APOBEC3F (A3F) or APOBEC3G (A3G). We previously reported that partial resistance to A3G could develop in these Vif-deficient viruses through a nucleotide A200-to-T/C transversion and a vpr null mutation, but these isolates were still susceptible to restriction by A3F. Here, long-term selection experiments were done to determine how these A3G-selected isolates might evolve to spread in the presence of A3F. We found that A3F, like A3G, is capable of potent, long-term restriction that eventually selects for heritable resistance. In all 7 instances, the selected isolates had restored Vif function to cope with A3F activity. In two isolates, Vif Q26-Q27 and Y26-Q27, the resistance phenotype recapitulated in molecular clones, but when the selected vif alleles were analyzed in the context of an otherwise wild-type viral background, a different outcome emerged. Although HIV-1 clones with Vif Q26-Q27 or Y26-Q27 were fully capable of overcoming A3F, they were now susceptible to restriction by A3G. Concordant with prior studies, a lysine at position 26 proved essential for A3G neutralization. These data combine to indicate that A3F and A3G exert at least partly distinct selective pressures and that Vif function may be essential for the virus to replicate in the presence of A3F.
Subject(s)
Cytosine Deaminase/physiology , HIV-1/genetics , HIV-1/physiology , vif Gene Products, Human Immunodeficiency Virus/genetics , vif Gene Products, Human Immunodeficiency Virus/physiology , APOBEC-3G Deaminase , Alleles , Base Sequence , Cell Line , Cytidine Deaminase/physiology , DNA Primers/genetics , DNA, Viral/genetics , Genes, vif , HIV-1/pathogenicity , Host-Pathogen Interactions/genetics , Host-Pathogen Interactions/physiology , Humans , Mutagenesis, Site-Directed , Mutation , Selection, Genetic , T-Lymphocytes/physiology , T-Lymphocytes/virology , Virus Replication/genetics , Virus Replication/physiologyABSTRACT
The human cytidine deaminases APOBEC3G (A3G) and APOBEC3F (A3F) potently restrict human immunodeficiency virus type 1 (HIV-1) replication, but they are neutralized by the viral protein Vif. Vif bridges A3G and A3F with a Cullin 5 (Cul5)-based E3 ubiquitin ligase and mediates their proteasomal degradation. This mechanism has been extensively studied, and several Vif domains have been identified that are critical for A3G and A3F neutralization. Here, we identified two additional domains. Via sequence analysis of more than 2,000 different HIV-1 Vif proteins, we identified two highly conserved amino acid sequences, (81)LGxGxSIEW(89) and (171)EDRWN(175). Within the (81)LGxGxSIEW(89) sequence, residues L81, G82, G84, and, to a lesser extent, I87 and W89 play very critical roles in A3G/A3F neutralization. In particular, residues L81 and G82 determine Vif binding to A3F, residue G84 determines Vif binding to both A3G and A3F, and residues (86)SIEW(89) affect Vif binding to A3F, A3G, and Cul5. Accordingly, this (81)LGxGxSIEW(89) sequence was designated the (81)LGxGxxIxW(89) domain. Within the (171)EDRWN(175) sequence, all residues except N175 are almost equally important for regulation of A3F neutralization, and consistently, they determine Vif binding only to A3F. Accordingly, this domain was designated (171)EDRW(174). The LGxGxxIxW domain is also partially conserved in simian immunodeficiency virus Vif from rhesus macaques (SIVmac239) and has a similar activity. Thus, (81)LGxGxxIxW(89) and (171)EDRW(174) are two novel functional domains that are very critical for Vif function. They could become new targets for inhibition of Vif activity during HIV replication.
Subject(s)
Conserved Sequence , Cytidine Deaminase/metabolism , Cytosine Deaminase/metabolism , vif Gene Products, Human Immunodeficiency Virus/chemistry , APOBEC-3G Deaminase , Amino Acid Sequence , Animals , Binding Sites , Cytidine Deaminase/antagonists & inhibitors , Cytosine Deaminase/antagonists & inhibitors , Gene Products, vif/chemistry , HIV-1 , Macaca , Protein Binding , Protein Structure, Tertiary , Simian Immunodeficiency Virus/chemistry , Ubiquitin-Protein Ligases/metabolism , vif Gene Products, Human Immunodeficiency Virus/metabolism , vif Gene Products, Human Immunodeficiency Virus/physiologyABSTRACT
The long-term expression and the ability of a therapeutic gene to confer survival advantage to transduced cells are mandatory requirements for successful anti-HIV gene therapy. In this context, we developed lentiviral vectors (LVs) expressing the F12-viral infectivity factor (Vif) derivative Chim3. We recently showed that Chim3 inhibits HIV-1 replication in primary cells by both blocking the accumulation of retrotranscripts, independently of either human APOBEC3G (hA3G) or Vif, and by preserving the antiviral function of hA3G. These results were predictive of long-lasting survival of Chim3(+) cells after HIV-1 infection. Furthermore, Vif, like Vpr, deregulates cell-cycle progression by inducing a delay in G(2) phase. Thus, the aim of this study was to investigate the role of Chim3 on both cell survival and cell-cycle regulation after HIV-1 infection. Here, we provide evidence that infected Chim3(+) T cells prevail over either mock- or empty-LV engineered cells, show reduced G(2) accumulation, and, as a consequence, ultimately extend their lifespan. Based on these findings, Chim3 rightly belongs to the most efficacious class of antiviral genes. In conclusion, Chim3 usage in anti-HIV gene therapy based on hematopoietic stem cell (HSC) modification has to be considered as a promising therapeutic intervention to eventually cope with HIV-1 infection.
Subject(s)
CD4-Positive T-Lymphocytes/physiology , DNA, Viral/genetics , G2 Phase/physiology , Genetic Therapy , HIV-1/physiology , Virus Integration , vif Gene Products, Human Immunodeficiency Virus/physiology , Blotting, Southern , CD4-Positive T-Lymphocytes/virology , Cell Survival , Cells, Cultured , DNA, Viral/metabolism , Hematopoietic Stem Cells , Humans , Immunoprecipitation , Virus Replication , vpr Gene Products, Human Immunodeficiency Virus/physiologyABSTRACT
We examined a series of site-directed point mutants of human immunodeficiency virus type 1 (HIV-1) Vif for their interaction with cellular anti-viral factors APOBEC3G/APOBEC3F. Mutant viruses that display growth-defect in H9 cells did not counteract effectively APOBEC3G and/or APOBEC3F without exception, as monitored by single-cycle infectivity assays. While growth-defective mutants of Vif C-terminal region were unable to suppress APOBEC3G/APOBEC3F, some N-terminal region mutants did neutralize one of APOBEC3G/APOBEC3F. These data have suggested that members of APOBEC3 family other than APOBEC3G/APOBEC3F are not important for anti-HIV-1 activity. Furthermore, APOPEC3G/APOBEC3F were found to differently associate with Vif in virions as analyzed by equilibrium density centrifugation. Taken together, these results indicated that interaction of HIV-1 Vif and APOBEC3G is distinct from that between Vif and APOBEC3F.
Subject(s)
Cytidine Deaminase/physiology , Cytosine Deaminase/physiology , vif Gene Products, Human Immunodeficiency Virus/physiology , APOBEC-3G Deaminase , Cell Line , HumansABSTRACT
Several variants of APOBEC3H (A3H) have been identified in different human populations. Certain variants of this protein are particularly potent inhibitors of retrotransposons and retroviruses, including HIV-1. However, it is not clear whether HIV-1 Vif can recognize and suppress the antiviral activity of A3H variants, as it does with other APOBEC3 proteins. We now report that A3H_Haplotype II (HapII), a potent inhibitor of HIV-1 in the absence of Vif, can indeed be degraded by HIV-1 Vif. Vif-induced degradation of A3H_HapII was blocked by the proteasome inhibitor MG132 and a Cullin5 (Cul5) dominant negative mutant. In addition, Vif mutants that were incapable of assembly with the host E3 ligase complex factors Cul5, ElonginB, and ElonginC were also defective for A3H_HapII suppression. Although we found that Vif hijacks the same E3 ligase to degrade A3H_HapII as it does to inactivate APOBEC3G (A3G) and APOBEC3F (A3F), more Vif motifs were involved in A3H_HapII inactivation than in either A3G or A3F suppression. In contrast to A3H_HapII, A3H_Haplotype I (HapI), which differs in only three amino acids from A3H_HapII, was resistant to HIV-1 Vif-mediated degradation. We also found that residue 121 was critical for determining A3H sensitivity and binding to HIV-1 Vif.
Subject(s)
Cytosine Deaminase/genetics , Cytosine Deaminase/physiology , Genetic Variation , HIV-1/physiology , vif Gene Products, Human Immunodeficiency Virus/physiology , Amino Acid Sequence , Amino Acid Substitution , Aminohydrolases , Base Sequence , Cell Line , Cytosine Deaminase/antagonists & inhibitors , Cytosine Deaminase/chemistry , Genes, vif , HIV-1/genetics , HIV-1/pathogenicity , Haplotypes , Host-Pathogen Interactions/genetics , Host-Pathogen Interactions/physiology , Humans , Models, Molecular , Molecular Sequence Data , Plasmids/genetics , Proteasome Endopeptidase Complex/metabolism , Protein Structure, Tertiary , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Sequence Homology, Amino Acid , Transfection , vif Gene Products, Human Immunodeficiency Virus/chemistry , vif Gene Products, Human Immunodeficiency Virus/geneticsABSTRACT
The arms race between virus and host is a constant battle. APOBEC3 proteins are known to be potent innate cellular defenses against both endogenous retroelements and diverse retroviruses. However, retroviruses have developed their own methods to launch counter-strikes. Most primate lentiviruses encode a protein called the viral infectivity factor (Vif). Vif induces targeted destruction of APOBEC3 proteins by hijacking the cellular ubiquitin-proteasome pathway. Here we review the research that led up to the identification of A3G, the mechanisms by which APOBEC3 proteins can inhibit retroelements, and the counter-mechanisms that HIV-1 Vif has developed to evade its antiviral activities.